To address how MSCs impact a tumor specific CAR T cell attack, we engineered T cells with a second generation CD28Δ-ζ CAR that is deficient in IL2 secretion due to a mutation in the lck binding domain of CD28 [30]. The gene discussed is CD28; the disease is neoplasm.